ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
— ORR of 64% Observed in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer — ORR of 75% and One Complete Response Observed in Patients with 1L Head and Neck Cancer — ALX Oncology to Host Conference Call on November 16 at 5:00pm EST BURLINGAME, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint […]
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
Financing will enable Stargazer to advance development of STG-001 through a pivotal clinical study in Stargardt Disease BOSTON (PRWEB) NOVEMBER 09, 2020 Stargazer Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel treatment options for rare eye diseases, announced it has completed a Series A financing totalling $57 million from leading investors Novo Holdings, […]
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today […]
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
— Robust pipeline of drugs against validated oncology targets — — Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope — — Led by repeatedly successful management team — October 14, 2020 08:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline […]
Metacrine Announces Pricing of Initial Public Offering
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) — Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced the pricing of its initial public offering of 6,540,000 shares of its common stock at a public offering price of $13.00 per share. […]
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis SOUTH SAN FRANCISCO, Calif., September 14, 2020 – Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis, today announced the completion of its […]
Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering
PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering of 5,348,837 shares of common stock at a price to the public of $24.00 per share. […]
Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of […]
ALX Oncology Announces Pricing of Initial Public Offering
BURLINGAME, Calif., July 16, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $19.00 per share. All of the shares […]
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group48% NASH resolution without worsening of fibrosis across all […]
